X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial for ENV-101 (taladegib). The xCures platform also enables patients to find more suitable treatment options if they are ineligible.
Lead Product(s): Taladegib
Therapeutic Area: Oncology Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Endeavor Biomedicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 31, 2022
Details:
US FDA granted their IND for an intermediate Expanded Access Program (EAP) for the ERK inhibitor ulixertinib (BVD-523). This intermediate-sized expanded access program is currently open and available for physicians interested in treating their patients.
Lead Product(s): Ulixertinib
Therapeutic Area: Oncology Product Name: BVD-523
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
